Tag:

lung cancer

Latest Headlines

Latest Headlines

U.K.'s Owlstone wins $7M for cancer-detecting breathalyzer

Owlstone Medical has raised £4.9 million ($7 million) to fund the ongoing clinical trials of its diagnostic breathalyzer for lung and colon cancers.

Genomic Health launches solid tumor liquid biopsy test

Redwood City, CA-based Genomic Health launched its first liquid biopsy test Tuesday. The blood-based mutation test is intended to help physicians make treatment decisions regarding various stage IV solid cancers, including melanoma, breast, lung, ovarian and gastrointestinal stromal tumors.

'Tumor suppressor' gene appears to promote aggressive type of lung cancer

A gene found to be conserved across many species, called Nitrilase 1, was traditionally thought to act as a tumor suppressor by preventing the aggressive growth of cancers. Now researchers say this gene is acting in the opposite way and instead promoting cancer growth. And the results of this study may give rise to a new drug target for an increasingly drug-resistant type of lung cancer.

Qiagen backs liquid biopsy startup Exosome in $60M Series B

Diagnostics giant Qiagen has joined the syndicate of Exosome Diagnostics--helping to distinguish this liquid biopsy startup from its growing crowd of peers. The pair are already partnered under a 2014 lung cancer diagnostic development deal. The Cambridge, MA-based startup has raised a $60 million Series B round to launch its liquid biopsy test via its CLIA-certified lab as well as to seek out companion diagnostics deals with biopharmas.

Exosome Diagnostics reels in $17.6M for liquid biopsy development

Exosome Diagnostics raked in $17.6 million in a second round of Series B financing, bringing the total amount raised to $44.7 million. The company plans to use the funds to support the launch of a few of its products, including two blood-based lung cancer liquid biopsies, a urine-based prostate cancer liquid biopsy and a solid tumor panel.

Exosome Diagnostics reels in $17.6M for liquid biopsy development

Exosome Diagnostics raked in $17.6 million in a second round of Series B financing, bringing the total amount raised to $44.7 million. The company plans to use the funds to support the launch of a few of its products, including two blood-based lung cancer liquid biopsies, a urine-based prostate cancer liquid biopsy and a solid tumor panel.

GE gets FDA nod for low-dose CT lung cancer screening device

GE Healthcare got an FDA green light for its low-dose computer tomography (CT) lung cancer screening device, a feather in the company's cap as it deepens its dive into diagnostics imaging.

Veracyte reveals positive numbers for lung cancer test in NEJM

Veracyte has been generating cash for R&D and striking deals to expand its market reach. Now, the company is touting promising results for its bronchial genomic classifier for lung cancer diagnosis as it takes a deeper dive into the lung cancer testing market.

Veracyte reveals positive numbers for lung cancer test in NEJM

Veracyte has been generating cash for R&D and striking deals to expand its market reach. Now, the company is touting promising results for its bronchial genomic classifier for lung cancer diagnosis as it takes a deeper dive into the lung cancer testing market.

CMS finalizes plan to offer Medicare coverage for CT scans among smokers

In an effort to detect lung cancer, the Centers for Medicare & Medicaid Services finalized plans to offer Medicare coverage for CT scans, or low-dose computed tomography, among smokers aged 55-77.